|
Originally published In Press as doi:10.1074/jbc.M208810200 on September 24, 2002
J. Biol. Chem., Vol. 277, Issue 50, 48677-48684, December 13, 2002
Characterization of the Apoptosis Suppressor
Protein P49 from the Spodoptera littoralis
Nucleopolyhedrovirus*
Zifei
Pei §¶,
Galit
Reske ¶,
Qihong
Huang**,
Bruce
D.
Hammock ,
Yipeng
Qi§, and
Nor
Chejanovsky 
From the Entomology Department, Institute of Plant
Protection, Agricultural Research Organization, the Volcani Center, POB
6, Bet Dagan, 50250 Israel, the § Institute of Virology,
Wuhan University, Wuhan 430072, People's Republic of China, and
Department of Entomology, University of California,
Davis, California 95616
Received for publication, August 28, 2002, and in revised form, September 24, 2002
 |
ABSTRACT |
Two antiapoptotic types of genes, iap
and p35, were found in baculoviruses. P35 is a 35-kDa
protein that can suppress apoptosis induced by virus infection or by
diverse stimuli in vertebrates or invertebrates. iap
homologues were identified in insects and mammals. Recently, we have
identified sl-p49, a novel apoptosis suppressor gene and
the first homologue of p35, in the genome of the
Spodoptera littoralis nucleopolyhedrovirus. Here we show that sl-p49 encodes a 49-kDa protein, confirmed its primary
structure that displays 48.8% identity to P35, and performed
computer-assisted modeling of P49 based on the structure of P35. We
demonstrated that P49 is able to inhibit insect and human effector
caspases, which requires P49 cleavage at Asp94.
Finally we identified domains important for P49's antiapoptotic function that include a reactive site loop (RSL) protruding from a
-barrel domain. RSL begins at an amphipathic 1 helix, traverses the -sheet central region, exposing Asp94 at the apex,
and rejoins the -barrel. Our model predicted seven -helical motifs, three of them unique to P49. -Helical
motifs 1, 2, and 4' were
required for P49 function. The high structural homology between
P49 and P35 suggests that these molecules bear a scaffold common to
baculovirus "apoptotic suppressor" proteins. P49 may serve as a
novel tool to analyze the contribution of different components of the
caspase chain in the apoptotic response in organisms not related phylogenetically.
 |
INTRODUCTION |
Apoptosis is a normal physiological cell suicide program highly
conserved among vertebrates and invertebrates (1-4). This cell death
program plays a critical role during normal development, tissue
homeostasis, eliminating from the organism unwanted cells, including
damaged and virus-infected cells. Thus, animal viruses have evolved
ways to evade, delay, or suppress this important cell defense strategy
(for a review, see Ref. 5).
Baculoviruses possess two types of genes with antiapoptotic activity,
iap (inhibitor of apoptosis) and
p35, that can suppress apoptosis induced by virus infection
or by diverse stimuli in vertebrates or invertebrates (6-9). Cellular
homologues of iap genes were identified in the genomes of
insects and mammals (10-12). P35, a 35-kDa protein encoded by the
p35 gene of the Autographa californica multiple
nucleopolyhedrovirus
(AcMNPV),1 inhibits a broad
range of caspases, including human and insect caspases (13-17),
activated during programmed cell death (reviewed in Ref. 18). The
crystal structure of P35 was determined (19), providing insight into
the mechanism of caspase inhibition (20). The most remarkable feature
of P35's structure is the presence of a large loop domain (residues
60-98), called reactive site loop (RSL), protruding above a central
-sheet core. The RSL is exposed to the solvent and contains at its
apex the caspase cleavage site Asp87 Gly88
in the caspase recognition motif
84DQMD87 (19, 20). The RSL is maintained and
stabilized by a single amphipathic 1-helix that
traverses and interacts with the top of the -sheet core (19).
Recently, we have identified sl-p49 (previously designated
slp49), a functional apoptosis suppressor gene and the first
homologue of the p35 gene, in the genome of the
Spodoptera littoralis nucleopolyhedrovirus (21).
Sl-p49 encodes a predicted 49-kDa protein that showed 48.8%
identity to P35. We took advantage of the high degree of similarity of the putative P49 molecule to P35 and modeled P49 utilizing the P35
structure as the template of reference. In this study, we report for
the first time the expression, identification, and functional activity
of P49. We demonstrate that P49 is able to inhibit insect and human
effector caspases that require cleavage at Asp94 for
function and characterize domains important for the antiapoptotic function of P49.
 |
EXPERIMENTAL PROCEDURES |
Cell Lines and Viruses--
Spodoptera frugiperda
SF9, Bombyx mori BmN, and Trichoplusia ni TN368
(22) cells were maintained and propagated in TNM-FH medium supplemented
with 10% heat-inactivated fetal bovine serum (23). Wild type AcMNPV
E-2 strain, S. littoralis nucleopolyhedrovirus E-15 strain,
and recombinant AcMNPV viruses and v P35K/pol+ were described
previously (16, 21, 23).
Marker Rescue Assay and Isolation of Recombinant
Viruses--
The ability of an antiapoptotic gene to enable
replication of P35-defective AcMNPV viruses, inhibiting apoptosis of
SF9 cells, was monitored by microscopic observation of the presence of
viral polyhedra in the nuclei of infected cells (7, 8, 21). Routinely,
1 µg of v P35K/pol+ DNA and 1 µg of tested plasmid DNA were
co-transfected into 4 × 105 SF9 cells using
Lipofectin (Invitrogen) in triplicates. 3-4 days after
transfection, the cells were examined by light microscopy for the
presence of polyhedra. The rescued virus yields were evaluated by
titration in SF9 cells and counting the number of nonapoptotic polyhedra-positive plaques (16, 21).
Cloning of B. mori Caspase-1--
mRNA was isolated from BmN
cells by using an mRNA extraction kit (Qiagen). Degenerate primers
were designed according to the consensus amino acid sequence among the
members of the insect caspase family, 5'-CA(A/G)GC(A/C/G/T)TG(T/C)C
A(A/G)GG(A/C/G/T)GA-3' and
5'-TGCAT(A/G)(A/T)ACCA(A/C/G/T)GA(A/C/G/T)CC-3'. Reverse PCR was
performed to obtain full-length B. mori caspase-1 cDNA,
and 5'-RACE and 3'-RACE were performed from BmN mRNA by using a
5'-RACE system (Invitrogen) and 3'-RACE kit (Takara), respectively. PCR primer 5'-AGAGTAATAACCTGGTACCGT-3' and a kit primer were used in the
5'-RACE PCR, and the primer 5'-TGGAGAAACACAACTCGTG-3' and a kit primer
were used in the 3'-RACE PCR. All amplified fragments were cloned into
HincII site of pTZ19U and sequenced.
Caspase Assays--
For caspase inhibition assays, serial
dilutions of wild type or mutated P49-His6 in assay buffer
50 mM HEPES (pH 7.4), 50 mM NaCl, 0.1% CHAPS,
10% sucrose, and 10 mM DTT were mixed with equal volumes
of caspase-containing assay buffer (purified B. mori
caspase-His6 (25 pmol) or active recombinant human
caspase-3 hCPP32 (0.3 pmol, 2 units; Biomol, Inc.), preactivated for 15 min with 10 mM DTT. Ac-DEVD-p-nitroanilide (200 µM) was added, and the reaction was monitored
colorimetrically at 405 nm using an enzyme-linked immunosorbent assay
reader (Tecan GmbH). Values, reported as the rate of product formation,
correspond to the average of triplicate assays taken during linear
product release within the first 10% of each reaction.
S. frugiperda Apoptotic Extracts--
SF9 cells were collected
at various time points after vAc p35/pol+ infection and suspended in
a solution of 10 mM HEPES (pH 7.0), 0.1% CHAPS, 5 mM DTT, and 2 mM EDTA containing the protease inhibitor mixture E-64 (100 µM), leupeptin (100 µM), pepstatin A (1 µM), aprotinin (2 µg/ml), and phenylmethylsulfonyl fluoride (1 µM)
(Calbiochem). After one freeze-thaw cycle, the cells were subjected to
Dounce homogenization. The cells lysates were clarified by
centrifugation and stored at 80 °C.
Protein Expression and Purification--
B. mori
caspase-1 was cloned into NdeI and XhoI sites of
PET23b (Novagen) to generate the plasmid pBm-caspase-1 with a
C-terminal His6 tag. p35 was amplified from the
plasmid pIE1hr-p35 (24) by PCR using the primers
5'-GGAATTCCATATGTGTGTAATTTTTCC-3' and
5'-CCGCTCGAGTTTAATTGTGTTTAATA-3' and cloned into NdeI and XhoI sites of pET22b(+). Sequencing confirmed that the
p35 clone was correct, and its 3'-end was fused with the His
tag of pET. The recombinant proteins were expressed in
Escherichia coli BL21 (DE3) after induction with 1 mM isopropyl- -D-thiogalactopyranoside. The cells were collected and suspended in ice-cold 20 mM Tris (pH 8.0) and 500 mM NaCl containing the
protease inhibitors E-64 (100 µM),
phenylmethylsulfonyl fluoride (1 µM), pepstatin A (1 µM), aprotinin (2 µg/ml), and 1 mg/ml lysozyme. After
lysis and further clarification, the extracts were mixed with
Ni2+-charged resin (Ni2+-nitrilotriacetic acid;
Qiagen) in binding buffer (20 mM Tris (pH 8.0), 5 mM imidazole, and 500 mM NaCl). Unbound
material was washed with 20 mM imidazole-containing binding
buffer. Bound protein was eluted with 250 mM
imidazole-containing binding buffer and was >95% pure as judged by
Coomassie-stained polyacrylamide gel analysis. Protein
concentration was measured using the Bio-Rad protein assay kit.
B. mori caspase-1 active concentrations were determined by
titration with DEVD-CHO as described before (25).
P49 Expression--
sl-p49 was amplified from the
plasmid pKS2 (21) by PCR using the primers
5'-CCGGAATTCATGTGTGTACTGATACCAAC-3' and
5'-ATAGTTTAGCGGCCGCTATATCTATGTAAATGTTACG-3' and subcloned in Bluescript
(Stratagene). The obtained plasmid pBlue-49 was subsequently digested
with EcoRI and NotI and
subcloned into pET22b(+), to provide it with a
C-terminal His6 tag. The resultant plasmid was digested
with Bpu1102I, and the cohesive end was treated with Klenow.
The complete sl-p49-His open reading frame was rescued by
subsequent digestion with EcoRI and subcloning into
EcoRI- and StuI-digested pFastBacI (Invitrogen)
to get p49 FastBac-His and, after it, the corresponding BACmid bacp49H
by following the manufacturer's instructions (Invitrogen). bacp49H DNA
was transfected to SF9 cells to produce the recombinant baculovirus vAc49H. DNA sequencing confirmed the identity of plasmids and viral
constructs. 5 × 106 SF9 cells infected with
recombinant baculoviruses (multiplicity of infection of 25) expressing
either (a) P49 or (b) P49H were harvested at
48 h after infection in lysis buffer. After cell disruption by
freezing and thawing, the clarified lysates were (a)
subjected to SDS-PAGE, and the gel was stained with Coomassie Blue
(overexpressed P49 was identified by comparing the polypeptides synthesized in extracts from vAcP49- and wild type AcMNPV-infected cells) or (b) mixed with Ni2+-conjugated agarose
beads (Qiagen) in binding buffer for 2 h at 4 °C. Washing and
elution were performed with 30 and 250 mM imidazole, respectively.
Immunoblot Analysis--
Proteins were subjected to SDS-PAGE and
to immunoblot analysis (26, 27) using either anti-P49 (prepared by
injection of P49 into rabbits using standard procedures) or mouse
monoclonal anti-His antisera (Invitrogen).
P49 Modeling--
Computer-assisted modeling of P49 was based on
the recently determined structure of P35 (19), exploiting the
availability of the Swiss-Model and 3D-PSSM Web server Biomolecular
Modeling Laboratory at the Imperial Cancer Research Fund (28, 29).
IVT P49 Cleavage Assays--
The T7 promoter-containing plasmid
pBlue-P49-stop was generated by exchanging the C-terminal
BglII-SacI fragment of pBlue-P49 with the
homologous fragment from pKS2 (21). Coupled transcription-translation reactions were performed using rabbit reticulocyte lysates and [35S]Met-Cys label (PerkinElmer Life Sciences) as
specified by the TNT manufacturer (Promega Corp.). Apoptotic
extracts containing S. frugiperda protease (16) or activated
caspases were incubated for 30 min with or without inhibitors and then
mixed with 35S-labeled in vitro translated P49.
Inhibitors utilized included protease inhibitor mixture (described
above), and caspase-II group-specific inhibitor DEVD-CHO (10 µM). All reaction mixtures (20 µl) contained 100 mM HEPES (pH 7.5), 2 mM DTT, 0.1% CHAPS, and
10% sucrose. After a 2-h incubation at 30 °C, the samples were
terminated by boiling and subjected to SDS-PAGE in a 15% acrylamide
gel followed by fluorography.
P49 Mutagenesis--
Mutations in P49 were generated in
pBlue-P49-stop by using overlap extension polymerase chain reaction
with complementary primers containing the desired mutation (30). The
primers utilized were as follows (the mutation sites are underlined,
and only one primer of the complementary pair is described for
simplicity): C2A,
5'-AACGGCAAAATGGCTGTACTGATACCAACATTC-3'; D28A,
5'-TCGATGCGCGCTCTGATCTATGTG-3'; S55K,
5'-GCGCTAAATATTAAGGGACCCCTCGTGTGCG-3'; R63Q,
5'-CGTGAATAGGGTGTCCATGCACATTGTG-3'; V69K,
5'-CCATGCACATTAAGCACATGTACAGATCG-3'; I76K,
5'-CAGATCGCACAAAGATAGGGTCTTTGATA-3'; I76Y,
5'-ACAGATCGCACTACGATAGGGTC-3'; I76P,
5'-GTACAGATCGCACCCCGATAGGGTCTTTG-3'; F80K,
5'-CGATAGGGTCAAAGATAAATTCAACAAAT-3'; T91A,
5'-ACATATTCGGCGGCCGTGACCGATGGCG-3'; D94A,
5'-CGACCGTGACCGCTGGCGGTGGAGCCGAT-3'; S113A,
5'-TGTCTGCATGGCACGCGGAGATCTTTTAA-3'; L125P,
5'-AATTACAAAAATTGTCCGCTCAACGAAATG-3'; V136P,
5'-TACGACGACCCCGAAAAGTTTAGAAAATAC-3'; Y142A,
5'-GTTTAGAAAAGCCTGTCTCAAACCTTTAA-3'; D159A,
5'-GAGCGGCAGCGCCGTCGGTGTGG-3'; K178A,
5'-GTTGAAACCGGCACTGTTGAATAACAAAAA-3'; I198K,
5'-CGGTCAAGTGAAGGTGCCGCTTATGCAC-3'; I205K,
5'-CTTATGCACGAAAAAAACGAAAACGGAAGCG-3'; M218A,
5'-CGTACGAAGTGGCGGCGATGATCAA-3'; L237P,
5'-TGTGCTGGAACGACCGAAGCGTTCCATGG-3'; L376P,
5'-AGTCTTGGAGAACCGTATTCGTTTGTAAA-3'; and K387A,
5'-TTATCGATTGGGCAACACACGAGACCAAT-3'. All mutations were
confirmed by DNA sequencing.
Determination of P49 Sequence--
P49 sequencing was performed
at The Protein Research Center (Israel Institute of Technology,
Technion, Haifa, Israel). The stained protein band from the SDS-PAGE
gel obtained from vAc49-infected Sf9 cell extracts (at 48 h
postinfection) was cut with a clean razor blade, and the proteins were
reduced with 10 mM DTT and modified with 100 mM
iodoacetamide in 10 mM ammonium bicarbonate. The gel piece
was treated with 50% acetonitrile in 10 mM ammonium bicarbonate to remove the stain from the proteins, dried, and rehydrated with 10 mM ammonium bicarbonate containing about
0.1 g of trypsin/sample followed by overnight incubation at
37 °C, and the resulting peptides were recovered with 60%
acetonitrile with 0.1% trifluoroacetate. The tryptic peptides were
resolved by reverse-phase chromatography on a 1 × 150-mm Vydac
C-18 column. The peptides were eluted using an 80-min linear gradient
of 5-95% acetonitrile with 0.025% trifluoroacetate in water at flow
rate of about 40 µl/min. The liquid from the column was
electrosprayed into an ion trap mass spectrometer (LCQ; Finnigan, San
Jose, CA). Mass spectrometry was performed in the positive ion mode
using repetitively full mass spectrometry scan followed by
collision-induced dissociation of the most dominant ion selected from
the first mass spectrometry scan. The mass spectrometry data
were compared with simulated proteolysis and collision-induced
dissociation of the proteins in the "nr" data base (NCBI) using
Sequest software (J. Eng and J. Yates, University of Washington and Finnigan).
 |
RESULTS |
P49 Structure--
To learn about the relationship between the
structure of P49 structure and its possible function, we performed
computer-assisted modeling of P49 based on the recently determined
structure of the pancaspase inhibitor P35 (19) (see "Experimental
Procedures"). This comparison predicted several domains important for
P49-function. (I) P49 domains of high homology to P35 (both
polypeptidic chains of 236 and 299 amino acids are depicted in Fig.
1 in blue and green, respectively) included the following: (a)
the -core, composed of a -barrel domain with a large insertion,
which forms the reactive site loop (Fig. 1, RSL). The RSL
begins at the amphipathic 1-helix (between
Val69 and Phe83, Figs. 1 and 7A) and
traverses the -sheet central region, exposing the Asp94
residue at the apex, in the context of the putative caspase-cleavable motif 91TVTD94 G (which corresponds to the P35
caspase-cleavable motif 84DMQD87 G (19)) and
follows downwards rejoining the -barrel; (b) three additional -helical domains, 2 (between residues
Gly115 and Asn127), 3 (between
residues Tyr133 and Pro146), and
4 (between residues Ile231 and
Arg236) (Fig. 1); (c) a side loop (indicated as
loop 3 and L3 in Fig. 1, A
and B, respectively) between amino acids Leu147
and Lys167 larger than the correspondent P35 loop (between
Lys140 and Asp147). (II) The C terminus of P49
(between Lys346 and Ile446), homologue to the C
terminus of P35 (between Lys259 and Ile298), as
predicted by secondary structure analysis, is shown in Fig. 1B (21). (III) -Helical regions predicted by secondary
structure analysis that are not present in P35 (Fig. 1B) are
designated 4' (between residues Leu237 and
Asn247), 5 (between residues
Asn279 and His298), and 6
(between residues Val364 and Ile383).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 1.
A, P49 model. Three-dimensional
superimposition of P49 (blue chain amino acids 1-236) on the
resolved crystal structure of P35 (green chain, amino acids 1-299; Protein Data Bank
code 1P35) (20). Main structural elements are indicated. B,
P49-P35 alignment. Horizontal dots indicate gaps
made to optimize the alignment; vertical bars and
dots, identical and similar amino acids, respectively. The
major secondary structural elements are indicated in italic
type above and below each polypeptide
sequence. h, helix and -respective number;
s, strand. Identified loops are underlined.
L3, side loop 3; L2, C-terminal loop 2.
|
|
Since P35 was shown as a potent inhibitor of invertebrate and
vertebrate caspases, we proceeded to analyze the ability of P49 to
inhibit caspase activity.
P49 Function--
To study P49 function, we engineered
sl-p49 under the control of the strong baculoviral promoter
polyhedrin and isolated the correspondent baculovirus (vAcP49). We
overexpressed sl-p49 protein in insect cells, identified it
by protein-sequence analysis that confirmed the putative P49 sequence
(21), and used it to produce anti-P49 antiserum (see "Experimental
Procedures"). The antiserum was able to detect P49 synthesis in
vAcP49-infected SF9 cells (Fig. 2,
right panel, lane vAcP49).
To purify P49, we engineered it with a C-terminal His tag and expressed
it using the correspondent recombinant baculovirus vAcP49H (see
"Experimental Procedures"). First, we confirmed that the
recombinant gene sl-p49H indeed expressed a functional
protein (P49H) by using a marker rescue assay in which SF9 cells were
co-transfected with vAc P35/pol+ and a plasmid bearing
sl-p49H under the control of the sl-p49 promoter
(21). Recovery of the polyhedra-positive virus phenotype due to
suppression of apoptosis was indicative of a functional
sl-p49 gene (Table I) (21).
P49H was isolated from extracts of vAcP49H-infected SF9 cells (Fig. 2)
by affinity chromatography using Ni2+-conjugated agarose
beads. The identity of the isolated protein was confirmed by SDS-PAGE
electrophoresis followed by immunoblot analysis utilizing anti-P49
antiserum (Fig. 2, right panel, lanes marked P49H; the full-size P49
molecules are indicated by the arrow) and by reacting the
vAcP49H-infected cell extract and purified protein with anti-His tag
antiserum (Fig. 2, left panel, lanes vAcP49H and P49H, respectively). A smaller
polypeptide was detected by the anti-P49 antiserum, but its nature is
still under investigation, since it does not bind to the
Ni2+ column. Also, a higher nonspecific band (over 65 kDa)
that reacted with mock-infected and baculovirus-infected extracts was
observed consistently (Fig. 2, right panel).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 2.
Overexpression of P49 and His-tagged P49
using baculovirus vectors. SF9 cells were infected with vAcP49 or
vAcP49H at a multiplicity of infection of 25. Protein extracts were
prepared at 72 h postinfection and subjected to affinity
chromatography using Ni2+-conjugated agarose beads. The
crude extracts and purified P49 were subjected to SDS-PAGE followed by
immunoblot analysis with anti-His tag or anti-P49 antiserum
(left and right panel, respectively).
AcP49H and vAcP49, crude extract from vAcP49H-
and vAcP49-infected cells, respectively; P49H, purified
P49-His-tagged protein; AcMNPV and m.i., wild
type-infected and mock-infected cell extract, respectively. Molecular
markers (in kDa) are indicated on the right.
|
|
P49 Is an Inhibitor of Lepidopteran Caspases--
To
determine whether P49 is able to inhibit lepidopteran effector
caspases, we isolated and expressed caspase-1 of the silkworm B. mori (Fig. 3A), which is
homologue to S. frugiperda caspase-1 (Fig. 3B),
the main lepidopteran caspase responsible for executing the apoptosis
program (14, 16) (see below). Incubation of B. mori
caspase-1 with increasing amounts of affinity chromatography-purified P49-His6 resulted in complete inhibition of caspase
activity as monitored by the ability of the caspase to cleave the
specific substrate DEVD-p-nitroanilide (Fig.
4A). Our P49 model predicted that amino acid residues at positions P1-P4 in
the putative caspase recognition motif 91TVTD94
could be essential for caspase inhibition by P49. Thus, we mutated Asp94 and Thr91 residues and analyzed the
ability of the mutants to inhibit caspase activity. Indeed, the mutant
D94A was unable to inhibit B. mori caspase-1, and the
mutation T91A affected significantly the ability of P49 to inhibit the
caspase (Fig. 4A).

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 3.
A. Predicted amino acid sequence of the
B. mori caspase-1. The consensus catalytic site
of the caspase is underlined. B, comparison of
B. mori and S. frugiperda caspase-1 amino acid
sequences using the BLAST program. Identical and similar (+) residues
are indicated (middle line).
|
|

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 4.
Inhibition of insect and human effector
caspases by P49. Increasing amounts of P49H were incubated with
B. mori caspase-1 (purified by affinity chromatography; see
"Experimental Procedures") (A) or with human caspase 3 (Cpp32; Biomol, Inc.) (B). After 30 min, residual caspase
activity was determined colorimetrically at 405 nm using the specific
peptidic substrate Ac-DEVD-p-nitroanilide.
|
|
To investigate if P49 is able to inhibit a human effector caspase, we
performed the same assay using human caspase-3. As can be seen, P49
inhibited the human caspase-3, CPP32, in a dose-dependent manner (Fig. 4B). The apparent discrepancy in P49's
preference for human caspase-3 over B. mori caspase-1 (15 pmol and more than 100 pmol were required to completely inhibit the
former and the latter, respectively) was due to different amounts of
caspase utilized in each assay (0.3 and 25 pmol for human caspase-3 and B. mori caspase-1, respectively).
Asp94 Is Required for P49 Cleavage by
Caspases--
Caspase-inhibition by P35 requires cleavage of the
tetrapeptide motif 84DMQD87. Thus we expected
that caspase inhibition by P49 would require cleavage of
Asp94 in the 91TVTD94 motif,
positioned at the apex of RSL in our model. To test this hypothesis, we
incubated in vitro translated 35S-labeled P49
with affinity-purified B. mori caspase-1. As can be seen,
B. mori caspase-1 cleaved P49 to yield a large fragment of
about 39 kDa and a small fragment of about 9.9 kDa (Fig.
5, lane 1,
arrows with asterisks indicate the
cleaved fragments), corresponding to the sizes expected from cleavage
at the 91TVTD94 motif. P49 cleavage was
inhibited when the type II-caspase inhibitor DEVD-CHO (18) was added to
the mixture before the addition of P49 (Fig. 5, lane
2), but not when a mixture of protease inhibitors that do
not inhibit caspases was utilized (Fig. 5, lane
3). Moreover, we performed the same experiment utilizing the
two mutants in the 91TVTD94 motif: D94A and
T91A. Incubation of in vitro translated P49 mutant proteins
with purified B. mori caspase-1 showed that the D94A mutation abolished caspase-mediated cleavage of P49, whereas T91A did
not abolish it (Fig. 5, lanes 5 and 7,
respectively). Also, P49 cleavage by human caspase-3 was specific,
yielding the 39- and 9.9-kDa fragments, and required aspartate at
position 94 (Fig. 5, lanes 9-11).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 5.
D94A is required for P49 cleavage by effector
caspases. 35S-Labeled in vitro translated
wild type (wt) or D94A- or T91A-mutated P49 was incubated
for 30 min with B. mori caspase-1 (Bm) or human
caspase-3 (H.3.) and then subjected to SDS-PAGE and
autoradiography. When indicated, Ac-DEVD-CHO (DEVD) or
protease (Prot) inhibitors were added before the caspase
addition. The arrows indicate the uncleaved and cleaved
(39-kDa (*) and 9.9-kDa (**)) forms of P49. Molecular markers (in kDa)
are indicated on the left.
|
|
Baculovirus infection activates S. frugiperda caspase-1
(16). In order to investigate whether P49 could be cleaved by
apoptotic extracts containing S. frugiperda caspase-1,
in vitro translated 35S-labeled P49 was
incubated with extracts of SF9 insect cells prepared
at various time points after infection with vAc P35/pol+ (Fig.
6, lanes 1-4 and
7-11, indicated at the bottom). It can be seen
that P49 was cleaved by apoptotic extracts prepared at 12 and 24 h
postinfection to yield the 39- and 9.9-kDa fragments (Fig. 6,
lanes 4 and 9) identical in size to
those obtained by incubation of the protein with B. mori
caspase-1 (Fig. 6, lane 14). Again, P49 cleavage
was inhibited by Ac-DEVD-CHO (Fig. 6, lanes 1,
3, 10, and 15). No inhibition of P49
cleavage was observed with a mixture of protease inhibitors added to
the reaction mixture (Fig. 6, lane 9), neither if
P49 was incubated with extracts from wild type AcMNPV-infected cells
(that synthesize the apoptotic suppressor P35) or from mock-infected
SF9 cells (Fig. 6, lanes 5 and 6,
respectively). Furthermore, the timing of P49 cleavage correlated with
the induction of the effector caspase-1 in S. frugiperda
cells (16) at 12 h after infection with vAc P35/pol+ (compare
lanes 2, 4, and 7 in Fig.
6). Incubation of T91A and D94A mutants with the apoptotic extracts
resulted in cleaved and uncleaved polypeptides, respectively, as
obtained by their incubation with purified caspase-3 (Fig. 6,
lanes 7 and 8 and lanes
13 and 12, respectively).

View larger version (70K):
[in this window]
[in a new window]
|
Fig. 6.
Viral induced S. frugiperda
caspase and B. mori caspase-1 cleave P49 to
yield similar fragments. 35S-Labeled in
vitro translated wild type (wt; lanes
1-6, 9-11, 14, and 15) or
D94A (lanes 8 and 12) and T91A
(lanes 7 and 13) mutated P49 were
incubated with SF9 apoptotic (SfAE; lanes
1-4 and 7-11), mock-infected (Sf,
lane 6), or AcMNPV-infected (lane
5) extracts or purified B. morii caspase-1
(Bm, lanes 12-15), and the cleaved
polypeptides were resolved in a 15% SDS-polyacrylamide gel followed by
autoradiography. The cell extracts were prepared at 3, 12, or 24 h
postinfection (h.p.i.; lanes 1 and
2, lanes 3 and 4, and
lanes 5-11, respectively). When indicated,
Ac-DVED-CHO (DEVD) or nonspecific protease inhibitors
(Prot) were added to the reaction mixture (lanes
1, 3, 10, 15, and
9, respectively). The arrows indicate the
uncleaved and cleaved P49 (asterisks). Molecular markers (in
kDa) are indicated on the left.
|
|
Taken together, these results support the idea that the
Asp94 residue at the consensus caspase cleavage motif
91TVTD94 is required for caspase cleavage of
P49, to generate the fragments of 39 and 9.9 kDa.
P49 Putative Structure and Inhibition of
Apoptosis--
We performed a series of site-directed mutations in P49
to test predictions of the model and begin to map P49 domains important for suppression of apoptosis. For that purpose, plasmids bearing wild
type or mutated p49 and vAc P35/pol+ were transfected to SF9 cells and examined for their ability to rescue viral replication (polyhedra formation) inhibiting apoptosis. In parallel, we constructed recombinant baculoviruses to establish that indeed the mutant proteins
were stably expressed (see below).
First, we targeted the predicted P49 structural elements homologous to
P35. Our results are summarized in Table I. The importance of the RSL
for the function of P49 was confirmed by utilizing the mutants T91A and
D94A in the motif 91TVTD94 (Fig.
7A). As expected, both mutants
were unable to rescue apoptosis (Table I).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 7.
Location of mutated amino acid residues in
the P49 structure (amino acids 1-236). A, the amino
acid residues of the RSL, the amphipathic 1 helix facing the solvent,
and the hydrophobic amino acids facing the -core are indicated.
B, 45° rotation of A. Residues mutated in the
-core and the 2, 3, and
4 helixes are indicated. C, detailed
interaction between residues in helix 1 and the
-core. The images were created by using the program
Swiss-Model (29, 38) and based on P35 coordinates (Protein Data Bank
code 1P35) (20). The specific mutations performed are indicated in
Table I.
|
|
We investigated whether residues Val69, Ile76,
and Phe80, located at the hydrophobic phase of the helix
1 motif (Fig. 7, A and C),
interacted with the -core of the P49 molecule, as has been shown in
P35 helix 1 (20). Thus, disruption of possible
hydrophobic interactions by mutagenesis could abolish P49 antiapoptotic
function. To test this possibility, three neutral to charged mutations
(namely V69K, I76K, and F80K) were inserted separately in P49. Indeed, each of these P49 mutants lost its ability to inhibit apoptosis induced
by vAc P35/pol+ (Table I). In contrast, substitution of
Ile76 by the aromatic residue Tyr resulted in a functional
protein (Table I). Moreover, mutation R63Q of a residue predicted to be
at a turn preceding helix 1 (Fig. 7A) did not
affect the ability of P49 to rescue viral replication (Table I).
Mutation of Met218 (M218A), located in a -sheet of the
-core motif (Fig. 7, A and C) predicted to
interact with helix 1, resulted in nonfunctional P49
(Table I).
Mutations that could distort the stability of the -barrel motif were
predicted to result in loss-of-function P49. Thus, charged-to-neutral (Ala) and neutral-to-charged mutations D28A and S55K, respectively, in
putative -sheets of the -core motif (Fig. 7B) yielded
nonfunctional P49, in contrast to the alanine replacement mutations C2A
and S113A (Table I). Mutations D159A, K178A, I205K, and K387A of residues predicted to be located in loops of the -core motif or
facing the solvent (see Fig. 7B; data not shown) did not
affect the ability of P49 to suppress apoptosis (Table I).
Interestingly, the neutral-to-charged mutation I198K placed in a loop
(probably in the -core) resulted in nonfunctional P49. Mutation at
Y142A in helix 3 yielded nonfunctional P49 (Fig.
7B and Table I).
The contribution of P49's putative -helical regions
1, 2, 3,
4', and 6 of P49 to inhibit apoptosis was
analyzed by introducing proline residues (known to disrupt -helical
regions) to obtain the corresponding mutants I76P, L125P, V136P, L237P, and L376P. Mutants I76P, L125P, and L237P lost their ability to inhibit
apoptosis (Table I).
Insertion of six His residues (His6 tag) at the N terminus,
located at the center of the -barrel, resulted in a nonfunctional P49 in contrast to C-terminal insertion.
All of the mutant proteins were synthesized to comparable levels in
insect cells (shown in Fig. 8 for the
proteins that lost their ability to inhibit apoptosis described in
Table I; positive mutants C2A, V136P, D159A, and K387A were also
included).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 8.
Synthesis of wild type and mutated P49 in
insect cells. SF9 cells (105) were infected with
recombinant baculoviruses expressing wild type or mutant P49 proteins
(mutations indicated above the lanes). At 72 h postinfection, the cell extracts were subjected to SDS-PAGE and
immunoblot analysis using anti-P49 antiserum. Arrow, P49
size. A molecular marker (kDa) is indicated between the left
and right panels.
|
|
Taken together, the mutagenesis results support our model
of P49. Moreover, they indicate that at least the -helical regions 1, 2, and 4' are required
for P49's antiapoptotic function.
 |
DISCUSSION |
In this study, we expressed and analyzed the product of the
sl-p49 gene of the S. littoralis
nucleopolyhedrovirus. We found, as predicted by the nucleotide sequence
(21), that sl-p49 coded for a protein of about 49 kDa. The
putative P49 amino acid sequence was confirmed by amino acid
sequencing, and we built a model of P49, based on its homology to the
caspase inhibitor P35 from the A. californica
nucleopolyhedrovirus, whose crystal structure was recently resolved
(19). Our three-dimensional model of P49 included the N-terminal 236 amino acid residues. Also, we made some predictions based on the
analysis of the secondary structure of P49 and applied them to study
some features of the C-terminal part of the molecule (amino acid
residues 239-446). Thus, we identified the following: a -core,
three additional alpha helical domains, and a side loop.
-Core--
The -core was composed of a -barrel domain
with a large insertion that forms the RSL. The RSL begins at an
amphipathic 1 helix (between Val69 and
Phe83) (Figs. 1 and 7A) and traverses the
-sheet central region, exposing the Asp94 residue at the
apex, in the context of the putative caspase-cleavable motif
91TVTD94 G, and follows downwards, rejoining
the -barrel. We determined that indeed the amino acid residues
Thr91 and Asp94 were required for P49
antiapoptotic function (Table I), Asp94 for caspase
cleavage (Fig. 5), and Thr91 and Asp94 for
efficient caspase inhibition (Fig. 4). The amino acid residues of the
helix 1 domain, which face the -core, appear to
interact with the adjacent amino acid residues from the -sheet and
are required for the antiapoptotic function of P49. Thus, replacement of hydrophobic residues Val69, Ile76, and
Phe80 by charged residues abolished the ability of P49 to
rescue apoptosis (Table I), in contrast to their replacement by
hydrophobic residues (e.g. I76Y). These results are in
accordance with the role proposed for P35 helix 1 in
maintaining the structure of the RSL (19, 20). Moreover, whereas
cleavage of Asp87 of the caspase recognition motif
84DQMD87 of P35 was required for its
antiapoptotic activity, it was not sufficient for stable association
and inhibition of caspases (19, 20). Resolution of the crystal
structure of a mutant in P35- 1 helix (V71P) suggested
that it might be required to enable conformational changes after
cleavage required for the formation of a stable complex between P35 and
the caspase (20, 31, 32). A similar role may be attributed to
P49- 1 helix, and further studies will be required to
show P49-caspase association and the contribution of the
1 helix to the mechanism of apoptosis inhibition by P49.
The Thr residue at position P4 of the caspase cleavage
consensus motif is important to proper inhibition by caspases belonging to group II (18). The T91A mutation changed that specificity; thus, we
expected that caspase inhibition by this mutant should be less
effective. Indeed, caspase inhibition studies that we performed with
the T91A-purified P49 and B. mori caspase-1 validated that
hypothesis (Fig. 4). A possible explanation for the behavior of this
mutant is that although cleavage by caspase occurs, the P49 mutant
molecule does not remain bound to the caspase, and it dissociates from
it, failing to inhibit it irreversibly (16).
Additional -Helical Domains--
Three additional -helical
domains, 2 (between residues Gly115 and
Asn127), 3 (between residues
Tyr133 and Pro146), and 4
(between residues Ile231 and Arg236) (Figs. 1
and 7A) homologous to those present in the P35 structure (Fig. 1) (19) and -helical regions (predicted by secondary structure
analysis, that are not present in P35) were designated 4' (between residues Leu237 and
Asn247), 5 (between residues
Asn279 and His298), and 6
(between residues Val363 and Ile385). Our
mutagenesis data suggest that helical regions 1,
2, and 4' are required for P49 function
(Table I).
Side Loop--
A side loop (indicated as loop
3 and L3 in Fig. 1, A and
B, respectively) between amino acids Leu147 and
Lys167 was larger than the correspondent P35 loop (between
Lys140 and Asp147). Replacement of
Asp159 by Ala did not affect P49 function (Table I).
Also, our model suggested that the P49 N terminus would be
embedded in the -core and would be disturbed by introduction of the
six His residues of the His tag. Indeed, this mutated P49 was not
functional. Introduction of the six His residues of the His tag at the
C terminus did not affect P49 function, suggesting that the C terminus
of the protein could be facing the solvent.
Overall, analysis of the modeled P49 structure revealed a pretty good
correlation between mutational disruption of defined secondary
structures ( -helical regions and -sheets) (Fig. 7, A
and B) and loss of P49 function (Table I). Mutations in
intervening loops, predicted not to disrupt the secondary structure,
did not abolish P49's antiapoptotic function (Table I).
P49 was able to inhibit the insect effector B. mori
caspase-1 and S. frugiperda caspase activities as well as
the human effector caspase-3 (Fig. 4) and was cleaved by caspases to
yield 39- and 9.9-kDa fragments (Figs. 5 and 6). Despite the fact that
the caspase cleavage motif in P49 is 91TVTD94
and that in P35 is 84DQMD87, both
inhibit human caspase-3. This suggests that if P49 has a different
(broader) selectivity for caspases than P35, other structural elements
present in P49 and absent in P35 could confer it. In this respect, it
is noteworthy that the -helical regions of P49 1,
2, and 4' were required for its
antiapoptotic function. In contrast, helix 2 was not
required for P35 suppression of apoptosis (20).
The high structural homology of P49 and P35 suggests that these
molecules bear a scaffold common to baculovirus apoptotic suppressor
proteins that could be designated a P35-like family of proteins.
Indeed, P35-like proteins were identified in the genomes of the
baculoviruses BmNPV (33), CuniNPV (34), LsNPV (35), TnMNPV (36), and
SlpltMNPV (37). It will be interesting to search for the presence of
more homologous proteins in the animal kingdom and more specifically in
the genomes of arthropods, the natural hosts of baculoviruses.
Moreover, our results indicate that P49 may serve as a novel tool to
analyze the contribution of different components of the caspase chain
participating in the apoptotic response in organisms not related phylogenetically.
 |
FOOTNOTES |
*
This work was supported by Israel Science Foundation Grant
426/99-3 and in part by Fogarty International Research Collaboration Award Grant TW01219, and United States Department of Agriculture Grant 35302-09919 (to B. D. H.) contribution from the Agricultural Research Organization (The Volcani Center, Bet Dagan, Israel) No. 415/02.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF448494.
¶
These two authors contributed equally to this work.
**
Present address: The Scripps Research Institute, 10550 N. Torrey
Pines Rd., La Jolla, CA 92307.

To whom correspondence should be addressed: Entomology Dept.,
Institute of Plant Protection, Agricultural Research Organization, The
Volcani Center, POB 6, Bet Dagan, 50250 Israel. Tel.: 972-3-9683694; Fax: 972-3-9604180; E-mail:
ninar@volcani.agri.gov.il.
Published, JBC Papers in Press, September 24, 2002, DOI 10.1074/jbc.M208810200
 |
ABBREVIATIONS |
The abbreviations used are:
AcMNPV, A.
californica multiple nucleopolyhedrovirus;
RSL, reactive site
loop;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio)]-1-propanesulfonic acid;
DTT, dithiothreitol;
DEVD, Asp-Glu-Val-Asp-CHO.
 |
REFERENCES |
| 1.
|
Jacobson, M. D.,
Weill, M.,
and Raff, M. C.
(1997)
Cell
88,
347-354[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Steller, H.
(1995)
Science
267,
1445-1449[Abstract/Free Full Text]
|
| 3.
|
Clem, R.
(2001)
Cell Death Differ.
8,
137-143[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Chang, H. Y.,
and Yang, X.
(2000)
Microbiol. Mol. Biol. Rev.
64,
821-846[Abstract/Free Full Text]
|
| 5.
|
Teodoro, J. G.,
and Branton, P.
(1997)
J. Virol.
71,
1739-1746[Medline]
[Order article via Infotrieve]
|
| 6.
|
Miller, L. K.,
Kaiser, W. J.,
and Sehsagiri, S.
(1998)
Semin. Virology
8,
445-452[CrossRef]
|
| 7.
|
Birnbaum, M. J.,
Clem, R. J.,
and Miller, L. K.
(1994)
J. Virol.
68,
2521-2528[Abstract/Free Full Text]
|
| 8.
|
Crook, N. E.,
Clem, R. J.,
and Miller, L. K.
(1993)
J. Virol.
67,
2168-2174[Abstract/Free Full Text]
|
| 9.
|
Clem, R. J.,
and Miller, L. K.
(1994)
Mol. Cell. Biol.
14,
5212-5222[Abstract/Free Full Text]
|
| 10.
|
Liston, P.,
Roy, N.,
Tamai, K.,
Lefebvre, C.,
Baird, S.,
Chertonhorvat, G.,
Farahani, R.,
Mclean, M.,
Ikeda, J. E.,
Mackenzie, A.,
and Korneluk, R. G.
(1996)
Nature
379,
349-353[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Duckett, C. S.,
Nava, V. E.,
Gedrich, R. W.,
Clem, R. J.,
Vandongen, J. L.,
Gilfillan, M. C.,
Shiels, H.,
Hardwick, J. M.,
and Thompson, C. B.
(1996)
EMBO J.
15,
2685-2694[Medline]
[Order article via Infotrieve]
|
| 12.
|
Hay, B. A.,
Wassarman, D. A.,
and Rubin, G. M.
(1995)
Cell
83,
1253-1262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Xue, D.,
and Horvitz, H. R.
(1995)
Nature
377,
248-251[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Ahmad, M.,
Srinivasula, S. M.,
Wang, L.,
Litwack, G.,
Fernandes-Alnemri, T.,
and Almemri, E. S.
(1997)
J. Biol. Chem.
272,
1421-1424[Abstract/Free Full Text]
|
| 15.
|
Bump, N. J.,
Hackett, M.,
Hugunin, M.,
Seshagiri, S.,
Brady, K.,
Chen, P.,
Ferenz, C.,
Franklin, S.,
Ghayur, T., Li, P.,
Licari, P.,
Mankovich, J.,
Shi, L. F.,
Greenberg, A. H.,
Miller, L. K.,
and Wong, W. W.
(1995)
Science
269,
1885-1888[Abstract/Free Full Text]
|
| 16.
|
Bertin, J.,
Mendrysa, S. M.,
Lacount, D. J.,
Gaur, S.,
Krebs, J. F.,
Armstrong, R. C.,
Tomaselli, K. J.,
and Friesen, P. D.
(1996)
J. Virol.
70,
6251-6259[Abstract]
|
| 17.
|
Zhou, Q.,
Krebs, J. F.,
Jnipas, S. J.,
Price, A.,
Alnemri, E. S.,
Tomaselli, K. J.,
and Salvensen, G. S.
(1998)
Biochemistry
37,
10757-10765[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Thornberry, N. A.,
and Labeznik, Y.
(1998)
Science
281,
1312-1316[Abstract/Free Full Text]
|
| 19.
|
Fisher, A. J.,
Cruz, W.,
Zoog, S. J.,
Schneider, Ch. L.,
and Friesen, P. D.
(1999)
EMBO J.
18,
2031-2039[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Zoog, S. J.,
Bertin, J.,
and Friesen, P. D.
(1999)
J. Biol. Chem.
274,
25995-26002[Abstract/Free Full Text]
|
| 21.
|
Du, Q.,
Lehavi, D.,
Faktor, O., Qi, Y.,
and Chejanovsky, N.
(1999)
J. Virol.
73,
1278-1285[Abstract/Free Full Text]
|
| 22.
|
Hink, W. F.
(1970)
Nature (Lond.)
225,
466-467
|
| 23.
| Summers, M. D., and Smith, G. E. (1978) Tex. Agric.
Exp. Stn. Bull. 1555
|
| 24.
|
Cartier, J. L,
Hershberger, P. A.,
and Friesen, P. D.
(1994)
J. Virol.
68,
7728-7737[Abstract/Free Full Text]
|
| 25.
|
Stennicke, H. R.,
and Salvesen, G. S.
(1999)
Methods Companion Methods Enzymol.
17,
313-319
|
| 26.
|
Chejanovsky, N.,
and Gershburg, E.
(1995)
Virology
209,
519-525[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Gershburg, E.,
Rivkin, H.,
and Chejanovsky, N.
(1997)
J. Virol.
71,
7593-7599[Abstract]
|
| 28.
|
Kelley, L. A,
MacCallum, R. M.,
and Sternberg, M. J. E.
(2000)
J. Mol. Biol.
299,
501-522[CrossRef]
|
| 29.
|
Guex, N.,
and Peitsch, M. C.
(1997)
Electrophoresis
18,
2714-2723[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Papworth, C.,
Bauer, J. C.,
and Braman, J.
(1996)
Strategies
9,
3-4
|
| 31.
|
de la Cruz, W.,
Friesen, P. D.,
and Fisher, A. J.
(2001)
J. Biol. Chem.
276,
32933-32939[Abstract/Free Full Text]
|
| 32.
|
Xu, G.,
Cirilli, M.,
Huang, Y.,
Rich, R. L.,
Myszka, D.,
and Wu, H.
(2001)
Nature
410,
494-497[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Kamita, S. G.,
Majima, K.,
and Maeda, S.
(1993)
J. Virol.
64,
455-463
|
| 34.
|
Afonso, C. L.,
Tulman, E. R., Lu, Z.,
Balinsky, C. A.,
Moser, B. A.,
Becnel, J. J.,
Rock, D. L.,
and Kutish, G. F.
(2001)
J. Virol.
75,
11157-11165[Abstract/Free Full Text]
|
| 35.
|
Qi, Y.,
Liu, Q.,
Peng, Y., Li, L.,
Pei, Z.,
and Liu, Y.
(2001)
Arch. Virol.
146,
2149-2163[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Dai, X.,
Shi, X.,
and Pang, Y., Su, D.
(1999)
J. Gen Virol.
80,
1841-1845[Abstract]
|
| 37.
|
Pang, Y., Yu, J.,
Wang, L., Hu, X.,
Bao, W., Li, G.,
Chen, C.,
Han, H., Hu, S.,
and Yang, H.
(2001)
Virology
287,
391-404[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Peistch, M. C.
(1995)
Bio/Technology
13,
658-660[CrossRef]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Q. Yu, T. Lin, G. Feng, K. Yang, and Y. Pang
Functional analysis of the putative antiapoptotic genes, p49 and iap4, of Spodoptera litura nucleopolyhedrovirus with RNAi
J. Gen. Virol.,
August 1, 2008;
89(8):
1873 - 1880.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. Guy and P. D. Friesen
Reactive-Site Cleavage Residues Confer Target Specificity to Baculovirus P49, a Dimeric Member of the P35 Family of Caspase Inhibitors
J. Virol.,
August 1, 2008;
82(15):
7504 - 7514.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Lannan, R. Vandergaast, and P. D. Friesen
Baculovirus Caspase Inhibitors P49 and P35 Block Virus-Induced Apoptosis Downstream of Effector Caspase DrICE Activation in Drosophila melanogaster Cells
J. Virol.,
September 1, 2007;
81(17):
9319 - 9330.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Escasa, H. A. M. Lauzon, A. C. Mathur, P. J. Krell, and B. M. Arif
Sequence analysis of the Choristoneura occidentalis granulovirus genome
J. Gen. Virol.,
July 1, 2006;
87(7):
1917 - 1933.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Li, P. Liston, N. Schokman, J. M. Ho, and R. W. Moyer
Amsacta moorei Entomopoxvirus Inhibitor of Apoptosis Suppresses Cell Death by Binding Grim and Hid
J. Virol.,
March 15, 2005;
79(6):
3684 - 3691.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Li, P. Liston, and R. W. Moyer
Functional Analysis of the Inhibitor of Apoptosis (iap) Gene Carried by the Entomopoxvirus of Amsacta moorei
J. Virol.,
February 15, 2005;
79(4):
2335 - 2345.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Garcia-Maruniak, J. E. Maruniak, P. M. A. Zanotto, A. E. Doumbouya, J.-C. Liu, T. M. Merritt, and J. S. Lanoie
Sequence Analysis of the Genome of the Neodiprion sertifer Nucleopolyhedrovirus
J. Virol.,
July 1, 2004;
78(13):
7036 - 7051.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|